Table 3. Differences in effectiveness and costs between treatments, per patient in the first year of treatment.

The ICERs show that we pay €278,099 per QALY if we use aflibercept instead of bevacizumab and that ranibizumab is dominated by bevacizumab, meaning it is costlier, but does not yield health benefit.

	Mean costs € (95-%CI)	Difference in costs Δ€	Mean effectiveness QALY (95-%CI)	Difference in effectiveness ΔQALY	ICER Δ€/ΔQALY
Ranibizumab	€ 33,137 (28,883–37,926)	€ 6,050	0.69 (0.66–0.73)	0.000	Dominated
Aflibercept	€ 31,119 (26,979–35,766)	€ 4,032	0.71 (0.67–0.74)	0.015	€ 278,099
Bevacizumab*	€ 27,087 (22,818–31,789)	-	0.69 (0.66–0.73)	-	-

QALY = quality-adjusted life year; ICER = incremental costs-effectiveness ratio; 95%-CI = 95%-confidence interval;

*Bevacizumab is comparator.